ABOUT 20th_BEF
​> REGISTRATION
​​> PRESENTERS
​​> ATTENDEES
> INVESTORS​​​​​
> SPONSORS​​
> SUPPORTERS​
> NETWORKING​

> ABOUT LAST YEAR

SPOtlight showcases

anocca ab

A biotechnology company developing next-generation immunotherapies via individualisation of therapeutic products to precisely leverage the immune system of each patient.

Due to both the immense complexity of immunity and the significant differences in the composition of the immune system between individuals, there is a need to individualise targeted immunotherapeutics. Anocca’s unique technology platform captures key information from the immune system of each individual to deliver a range of immunotherapies specifically tailored to target the disease attributes of each patient, and to work safely within the constraints of each patient’s immune system.

Anocca’s first clinical programs aim to deliver cellular therapies equipped either with targeting receptors from our receptor libraries that are tailored for defined groups of individuals, or equipped with targeting receptors that are created for each patient in a fully individualised manner.

​https://www.anocca.com/​

Beigene ltd.

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azaciditine) in China under a license from Celgene Corporation.

https://www.beigene.com/

bergenbio asa

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. 

The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. 

Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

​https://www.bergenbio.com/

Bone therapeutics SA

A leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an enhanced viscosupplement, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio as well as knowhow.
​
​http://www.bonetherapeutics.com

euronext

Euronext is the leading pan-European exchange in the Eurozone with nearly 1,430 issuers, representing a total market capitalization worth €3.3 trillion as of March 31st, 2020, including 27 major stocks in the Morningstar® Eurozone 50 Index℠. Euronext manages six national regulated and transparent cash and derivative markets in Amsterdam, Brussels, Dublin, Lisbon, Oslo and Paris, as well as a UK-based regulated securities market in London. Euronext has a strong diverse domestic and international client base, covering various products such as equities, Exchange Traded Funds (ETFs), warrants and certificates, bonds, equity derivatives, commodity derivatives and indices. In addition to its main regulated market, Euronext operates Euronext Growth and Euronext Access, simplifying access to listing of small and medium-sized companies. There are 1,100+ listed SMEs on Euronext markets. 481 can be considered as listed Tech companies operating in TMT/ICT (~305 companies), Cleantech (~65) and Life Sciences (~105). Overall over 4,700 institutional investors provide a deep investor pool. ​

​https://www.euronext.com

Immunicum AB

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.

https://immunicum.se/

msd

To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

http://www.msd.com/index.html

syneos health

Syneos Health™ is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together to create customer success. Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum. Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.

​https://www.syneoshealth.com/

vaxart, inc.

Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker symbol VXRT.​

https://vaxart.com/

---

*5 / 10 / 20 minute showcasing companies will be available shortly...